Cyproterone acetate in the treatment of hirsutism.
Cyproterone acetate (100 mg daily on the 5th-14th days of the normal cycle) together with ethinyl estradiol (0.05 mg daily on the 5th-25th days) was used for the treatment of hirsutism in 23 women for six months. This treatment caused a significant decrease in the severity of the hirsutism after only three months, the effect being maximal after six months. Sixty per cent of our patients reported being subjectively satisfied with the results. A relapse occurred, however, within three months of the end of the treatment in half the patients. The serum testosterone was significantly decreased after three months of treatment, but the changes in serum testosterone did not follow the changes in the clinical picture of hirsutism, suggesting that one facet in the favorable action of cyproterone acetate is an inhibition of the action of androgen on target cells. Various side effects, such as nausea, headache, loss of libido and depression, were reported very frequently, which undoubtedly limits the large scale use of this treatment, at least with the doses used in this study.
D000328:Adult; D003534:Cyproterone / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D004997:Ethinyl Estradiol; D003534:Cyproterone